Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Risk of Breast Cancer and Total Malignancies in Rheumatoid Arthritis Patients Undergoing TNF-α Antagonist Therapy: a Meta-analysis of Randomized Control Trials

  • Liu, Yang (Center for Nanoscale Characterization & Devices (CNCD), Wuhan National Laboratory for Optoelectronics (WNLO), School of Physics, School of Optical and Electronic Information, Huazhong University of Science and Technology (HUST)) ;
  • Fan, Wei (Department of Clinical Laboratory & Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) ;
  • Chen, Hao (Department of Clinical Laboratory & Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) ;
  • Yu, Ming-Xia (Department of Clinical Laboratory & Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University)
  • Published : 2014.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Context: Interest exits in whether TNF-alpha antagonists increase the risk of breast cancer and total malignancies in patients with rheumatoid arthritis (RA). Objectives: To analyze the risk of malignancies, especially breast cancer, in patients with RA enrolled in randomized control trials (RCTs). Methods: A systematic literature search for RCTs from 1 January 1998 to 1 July 2013 from online databases, such as PubMed, WILEY, EMBASE, ISI web of knowledge and Cochrane Library was conducted. Studies included RCTs that compared the safety of at least one dose of the five TNF-${\alpha}$ antagonists with placebo or methotrexate (MTX) (or TNF-${\alpha}$ antagonists plus MTX vs placebo plus MTX) in RA patients for more than 24 weeks and imported all the references into document management software EndNote${\times}6$. Two independent reviewers selected studies and extracted the data about study design, patients' characteristics and the type, number of all malignancies. Results: 28 RCTs from 34 records with 11,741 patients were analyzed. Of the total, 97 developed at least one malignancy during the double-blind trials, and breast cancer was observed in 17 patients (17.5% of total malignancies). However, there was no statistically significant increased risk observed in either the per protocol (PP) model (OR 0.65, 95%CI [0.22, 1.93]) or the modified intention to treat (mITT) model (OR 0.75, 95%CI [0.25, 2.21]). There were also no significant trend for increased risk of total malignancies on anti-TNF-${\alpha}$ therapy administered at approved doses in either model (OR, 1.06, 95%CI [0.64, 1.75], and OR, 1.30, 95%CI [0.80, 2.14], respectively). As to the two models, modified intention to treat model analysis led to higher estimation than per protocol model analysis. Conclusions: This study did not find a significantly increased risk of breast cancer and total malignancies in adults RA patients treated with TNF-${\alpha}$ antagonists at approved doses. However, it cannot be ignored that more patients developed malignancies with TNF-${\alpha}$ antagonists therapy compared with patients with placebo or MTX, in spite of the lack of statistical significance, so that more strict clinical trials and long-term follow-up are needed, and both mITT and PP analyses should be used in such safety analyses.

Keywords

References

  1. Arnett FC (1989). Revised criteria for the classification of rheumatoid arthritis. Bull Rheum Dis, 38, 1-6.
  2. Abe T, Takeuchi T, Miyasaka N, et al (2006). A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol, 33, 37-44.
  3. Aaltonen KJ, Virkki LM, Malmivaara A, et al (2012). Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PloS One, 7, 30275. https://doi.org/10.1371/journal.pone.0030275
  4. Bathon JM, Martin RW, Fleischmann RM, et al (2000). A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med, 343, 1586-93. https://doi.org/10.1056/NEJM200011303432201
  5. Breedveld FC, Weisman MH, Kavanaugh AF, et al (2006). The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum, 54, 26-37. https://doi.org/10.1002/art.21519
  6. Bongartz T, Sutton AJ, Sweeting MJ, et al (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295, 2275-85. https://doi.org/10.1001/jama.295.19.2275
  7. Bejarano V, Quinn M, Conaghan PG, et al (2008). Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum, 59, 1467-74. https://doi.org/10.1002/art.24106
  8. Bongartz T, Warren FC, Mines D, et al (2009). Etanercept therapy in rheumatoid arthritis and the risk of malignancies:a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis, 68, 1177-83. https://doi.org/10.1136/ard.2008.094904
  9. Balkwill F (2009). Tumour necrosis factor and cancer. Nat Rev Cancer, 9, 361-71. https://doi.org/10.1038/nrc2628
  10. Chen DY, Chou SJ, Hsieh TY, et al (2009). Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med Assoc, 108, 310-9. https://doi.org/10.1016/S0929-6646(09)60071-1
  11. Choy E, McKenna F, Vencovsky J, et al (2012). Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology (Oxford, England), 51, 1226-34. https://doi.org/10.1093/rheumatology/ker519
  12. Detert J, Bastian H, Listing J, et al (2013). Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigatorinitiated study. Ann Rheum Dis, 72, 844-50. https://doi.org/10.1136/annrheumdis-2012-201612
  13. Emery P, Breedveld FC, Hall S, et al (2008). Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet, 372, 375-82. https://doi.org/10.1016/S0140-6736(08)61000-4
  14. Emery P, Fleischmann RM, Moreland LW, et al (2009). Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum, 60, 2272-83. https://doi.org/10.1002/art.24638
  15. Emery P, Fleischmann RM, Doyle MK, et al (2013). Golimumab, a human anti-TNF monoclonal antibody, injected subcutaneously every 4 weeks in MTX-naive patients with active rheumatoid arthritis: 1-year and 2-year clinical, radiological, and physical function findings of a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. Arthrit Care Res.
  16. Furst DE, Schiff MH, Fleischmann RM, et al (2003). Adalimumab, a fully human anti tumor necrosis factoralpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol, 30, 2563-71.
  17. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al (2009). Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis, 68, 805-11. https://doi.org/10.1136/ard.2008.099291
  18. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al (2005). Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum, 52, 3381-90. https://doi.org/10.1002/art.21405
  19. Genta M S, Kardes H, Gabay C (2006). Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community. Joint Bone Spine, 73, 51-6. https://doi.org/10.1016/j.jbspin.2005.07.002
  20. Higgins JPT, Green S, Collaboration C (2008). Cochrane Handbook for Systematic Reviews of interventions. Wiley Online Library.
  21. Hayashi M, Kobayakawa T, Takanashi T, et al (2013). Golimumab reduces disease activity of rheumatoid arthritis for 1 year and strongly inhibits radiographic progression in Japanese patients: partial but detailed results of the GO-FORTH and GO-MONO studies. Clin Rheumatol , 32, 961-7. https://doi.org/10.1007/s10067-013-2210-x
  22. Jadad AR, Moore RA, Carroll D, et al (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 17, 1-12. https://doi.org/10.1016/0197-2456(95)00134-4
  23. J Sweeting M, J Sutton A, C Lambert P (2004). What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med, 23, 1351-75. https://doi.org/10.1002/sim.1761
  24. Kremer JM, Weinblatt ME, Bankhurst AD, et al (2003). Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum, 48, 1493-9. https://doi.org/10.1002/art.11142
  25. Klareskog L, van der Heijde D, de Jager JP, et al (2004). Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet, 363, 675-81. https://doi.org/10.1016/S0140-6736(04)15640-7
  26. Keystone EC, Kavanaugh AF, Sharp JT, et al (2004). Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum, 50, 1400-11. https://doi.org/10.1002/art.20217
  27. Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al (2006). A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis, 65, 1578-84. https://doi.org/10.1136/ard.2005.038349
  28. Kim H Y, Lee S K, Song Y W, et al (2007). A randomized, doubleblind, placebo-controlled, phase III study of the human antitumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR J Rheumatol, 10, 9-16. https://doi.org/10.1111/j.1479-8077.2007.00248.x
  29. Kay J, Matteson EL, Dasgupta B, et al (2008). Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebocontrolled, dose-ranging study. Arthritis Rheum, 58, 964-75. https://doi.org/10.1002/art.23383
  30. Keystone E, Heijde D, Mason D Jr, et al (2008). Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis:findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study. Arthritis Rheum, 58, 3319-29. https://doi.org/10.1002/art.23964
  31. Keystone EC, Genovese MC, Klareskog L, et al (2009). Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GOFORWARD Study. Arthritis Rheum, 68, 789-96.
  32. Keystone E, Genovese MC, Klareskog L, et al (2010). Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GOFORWARD study. Arthritis Rheum, 69, 1129-35.
  33. Kremer J, Ritchlin C, Mendelsohn A, et al (2010). Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum, 62, 917-28.
  34. Keystone EC, Combe B, Smolen J, et al (2012). Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford, England), 51, 1628-38. https://doi.org/10.1093/rheumatology/kes082
  35. Keystone EC, Genovese MC, Hall S, et al (2013). Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GOFORWARD Study Extension. J Rheumatol, 40, 1097-103. https://doi.org/10.3899/jrheum.120584
  36. Kavanaugh A, Fleischmann RM, Emery P, et al (2013). Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis, 72, 64-71. https://doi.org/10.1136/annrheumdis-2011-201247
  37. Keystone EC, van der Heijde D, Kavanaugh A, et al (2013). Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis. J Rheumatol, 40, 1487-97 https://doi.org/10.3899/jrheum.120964
  38. Lipsky PE, van der Heijde DM, St Clair EW, et al (2000). Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. The New England J Med, 343, 1594-602. https://doi.org/10.1056/NEJM200011303432202
  39. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al (2012). Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA, 308, 898-908. https://doi.org/10.1001/2012.jama.10857
  40. Moreland LW, Schiff MH, Baumgartner SW, et al (1999). Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med, 130, 478-86. https://doi.org/10.7326/0003-4819-130-6-199903160-00004
  41. Maini RN, Breedveld FC, Kalden JR, et al (1998). Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum, 41, 1552-63. https://doi.org/10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
  42. Moher D, Cook Dj, Eastwood S, et al (1999). Improving the quality of reports of meta-analysis of randomised controlled trial: the QUOROM statement. Quality of Reporting of Meta-analysis. Lancet, 354, 1896-900. https://doi.org/10.1016/S0140-6736(99)04149-5
  43. Maini R, St Clair EW, Breedveld F, et al (1999). Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet, 354, 1932-39. https://doi.org/10.1016/S0140-6736(99)05246-0
  44. Madhusudan S, Foster M, Muthuramalingam S R, et al (2004). A phase II study of etanercept (Enbrel), a tumor necrosis factor $\alpha$ inhibitor in patients with metastatic breast cancer. Clin Cancer Res, 10, 6528-34. https://doi.org/10.1158/1078-0432.CCR-04-0730
  45. Maini RN, Breedveld FC, Kalden JR, et al (2004). Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum, 50, 1051-65. https://doi.org/10.1002/art.20159
  46. Miyasaka N (2008). Clinical investigation in highly diseaseaffected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol, 18, 252-62. https://doi.org/10.3109/s10165-008-0045-0
  47. Moreland LW, O’Dell JR, Paulus HE, et al (2012). A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum, 64, 2824-35. https://doi.org/10.1002/art.34498
  48. Moulis G, Sommet A, Bene J, et al (2012). Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PloS One, 7, 48991. https://doi.org/10.1371/journal.pone.0048991
  49. Ni XJ, Xia TS, Zhao YC, et al (2012). Postmenopausal Hormone Therapy is Associated with in Situ Breast Cancer Risk. Asian Pac J Cancer Prev, 13, 3917-25. https://doi.org/10.7314/APJCP.2012.13.8.3917
  50. P LEB, Mouterde G, Barnetche T, Morel J, Combe B (2012). Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol, 39, 712-5. https://doi.org/10.3899/jrheum.110982
  51. Quinn MA, Conaghan PG, O’Connor PJ, et al (2005). Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 52, 27-35. https://doi.org/10.1002/art.20712
  52. St Clair EW, van der Heijde DM, Smolen JS, et al (2004). Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum, 50, 3432-43. https://doi.org/10.1002/art.20568
  53. Schiff M, Keiserman M, Codding C, et al (2008). Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebocontrolled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis, 67, 1096-103. https://doi.org/10.1136/ard.2007.080002
  54. Smolen J, Landewe RB, Mease P, et al (2009). Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis, 68, 797-804. https://doi.org/10.1136/ard.2008.101659
  55. Singh JA, Christensen R, Wells GA, et al (2009). A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ, 181, 787-96. https://doi.org/10.1503/cmaj.091391
  56. Taylor PC, Steuer A, Gruber J, et al (2004). Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum, 50, 1107-16. https://doi.org/10.1002/art.20123
  57. Tanaka Y, Harigai M, Takeuchi T, et al (2012). Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis, 71, 817-24. https://doi.org/10.1136/ard.2011.200317
  58. Takeuchi T, Miyasaka N, Zang C, et al (2013). A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. Mod Rheumatol, 23, 623-33. https://doi.org/10.3109/s10165-012-0742-6
  59. Tripsianis G, Papadopoulou E, Romanidis K, et al (2013). overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF-$\alpha$ and TGF-${\beta}1$. Asian Pac J Cancer Prev, 14, 6813-20. https://doi.org/10.7314/APJCP.2013.14.11.6813
  60. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al (2006). Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum, 54, 1063-74. https://doi.org/10.1002/art.21655
  61. Van der Heijde D, Klareskog L, Landewe R, et al (2007). Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum, 56, 3928-39. https://doi.org/10.1002/art.23141
  62. Van der Heijde D, Breedveld FC, Kavanaugh A, et al (2010). Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol, 37, 2237-46. https://doi.org/10.3899/jrheum.100208
  63. Weinblatt ME, Kremer JM, Bankhurst AD, et al (1999). A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New Engl J Med, 340, 253-9. https://doi.org/10.1056/NEJM199901283400401
  64. Weinblatt ME, Keystone EC, Furst DE, et al (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum, 48, 35-45. https://doi.org/10.1002/art.10697
  65. Weisman MH, Paulus HE, Burch FX, et al (2007). A placebocontrolled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford, England), 46, 1122-5. https://doi.org/10.1093/rheumatology/kem033
  66. Weinblatt ME, Bathon JM, Kremer JM, et al (2011). Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthrit Care Res, 63, 373-82. https://doi.org/10.1002/art.30115
  67. Wiens A, Correr CJ, Venson R, et al (2009). A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol, 28, 1365-73. https://doi.org/10.1007/s10067-009-1233-9
  68. Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST (2012). Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol, 31, 631-6. https://doi.org/10.1007/s10067-011-1895-y
  69. Weinblatt ME, Fleischmann R, Huizinga TW, et al (2012). Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology, 51, 2204-14. https://doi.org/10.1093/rheumatology/kes150
  70. Weinblatt ME, Bingham CO, Mendelsohn AM, et al (2013). Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis, 72, 381-9. https://doi.org/10.1136/annrheumdis-2012-201411
  71. Yu M, Zhou X, Niu L, et al (2013). Targeting Transmembrane TNF-$\alpha$ Suppresses Breast Cancer Growth. Cancer Res, 73, 4061-74. https://doi.org/10.1158/0008-5472.CAN-12-3946

Cited by

  1. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database vol.30, pp.2, 2015, https://doi.org/10.1111/fcp.12171
  2. Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses vol.35, pp.1, 2016, https://doi.org/10.1007/s10067-015-3115-7
  3. Gynecological cancers in patients with inflammatory rheumatic diseases vol.75, pp.1, 2016, https://doi.org/10.1007/s00393-016-0044-z
  4. Neutralization Versus Reinforcement of Proinflammatory Cytokines to Arrest Autoimmunity in Type 1 Diabetes vol.52, pp.3, 2017, https://doi.org/10.1007/s12016-016-8587-y
  5. Fas/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and β-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes vol.8, pp.1664-3224, 2017, https://doi.org/10.3389/fimmu.2017.00342
  6. Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-αIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence pp.1744-764X, 2017, https://doi.org/10.1080/14740338.2018.1400530
  7. Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database pp.2168-4804, 2018, https://doi.org/10.1177/2168479017728987
  8. Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome pp.02780232, 2018, https://doi.org/10.1002/hon.2525